COMPLETE Trial Follow-Up Duration
The COMPLETE trial had a median follow-up of 3 years 1.
Extended Follow-Up Details
The primary analysis of the COMPLETE trial, which randomized patients with ST-segment elevation myocardial infarction (STEMI) and multivessel coronary artery disease to either complete revascularization or culprit-lesion-only PCI, reported outcomes at a median follow-up of 3 years 1.
Key Findings at 3-Year Follow-Up
At this median 3-year follow-up period:
First coprimary outcome (cardiovascular death or myocardial infarction): 7.8% in complete revascularization vs 10.5% in culprit-lesion-only group (HR 0.74; 95% CI 0.60-0.91; P=0.004) 1
Second coprimary outcome (cardiovascular death, myocardial infarction, or ischemia-driven revascularization): 8.9% vs 16.7% (HR 0.51; 95% CI 0.43-0.61; P<0.001) 1
Timing Analysis
A pre-specified analysis examined the timing of nonculprit lesion PCI, with actual median timing of 1 day for in-hospital procedures and 23 days for post-discharge procedures 2. The benefit of complete revascularization was consistent regardless of timing (interaction P=0.62) 2.
Important Context
Landmark analyses demonstrated that the benefit of complete revascularization emerged primarily after 45 days, with an HR of 0.69 (95% CI 0.54-0.89) from 45 days onward, indicating that the clinical advantage manifests mainly over the long term rather than immediately 2.